JP2024037713A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2024037713A5 JP2024037713A5 JP2023145013A JP2023145013A JP2024037713A5 JP 2024037713 A5 JP2024037713 A5 JP 2024037713A5 JP 2023145013 A JP2023145013 A JP 2023145013A JP 2023145013 A JP2023145013 A JP 2023145013A JP 2024037713 A5 JP2024037713 A5 JP 2024037713A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- urothelial
- cocrystal
- fgfr3
- bladder cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010005003 Bladder cancer Diseases 0.000 claims 45
- 102100027842 Fibroblast growth factor receptor 3 Human genes 0.000 claims 26
- 101710182396 Fibroblast growth factor receptor 3 Proteins 0.000 claims 26
- 206010028980 Neoplasm Diseases 0.000 claims 26
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 26
- 201000011510 cancer Diseases 0.000 claims 26
- 201000005112 urinary bladder cancer Diseases 0.000 claims 26
- 239000013078 crystal Substances 0.000 claims 23
- 210000003205 muscle Anatomy 0.000 claims 23
- 238000000634 powder X-ray diffraction Methods 0.000 claims 20
- 230000005855 radiation Effects 0.000 claims 20
- 206010044412 transitional cell carcinoma Diseases 0.000 claims 19
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 claims 18
- 238000000034 method Methods 0.000 claims 17
- 239000003814 drug Substances 0.000 claims 13
- 229940079593 drug Drugs 0.000 claims 12
- 230000001394 metastastic effect Effects 0.000 claims 10
- 206010061289 metastatic neoplasm Diseases 0.000 claims 10
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims 9
- 229940074391 gallic acid Drugs 0.000 claims 9
- 235000004515 gallic acid Nutrition 0.000 claims 9
- 241001467552 Mycobacterium bovis BCG Species 0.000 claims 8
- 229960000190 bacillus calmette–guérin vaccine Drugs 0.000 claims 8
- 230000000750 progressive effect Effects 0.000 claims 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims 6
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims 6
- 239000002002 slurry Substances 0.000 claims 6
- 239000012458 free base Substances 0.000 claims 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 4
- 208000006593 Urologic Neoplasms Diseases 0.000 claims 4
- 150000001875 compounds Chemical class 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 238000002360 preparation method Methods 0.000 claims 4
- 239000002904 solvent Substances 0.000 claims 4
- 229960003966 nicotinamide Drugs 0.000 claims 3
- 235000005152 nicotinamide Nutrition 0.000 claims 3
- 239000011570 nicotinamide Substances 0.000 claims 3
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- OYUCEQFRNJABJW-UHFFFAOYSA-N CC1=C(C2=CN3N=CC(Cl)=C3C(OC(CO)C(C=C3)=NC=C3F)=C2)N=NN1C(CC1)CCN1C#N Chemical compound CC1=C(C2=CN3N=CC(Cl)=C3C(OC(CO)C(C=C3)=NC=C3F)=C2)N=NN1C(CC1)CCN1C#N OYUCEQFRNJABJW-UHFFFAOYSA-N 0.000 claims 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 2
- 206010014733 Endometrial cancer Diseases 0.000 claims 2
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- 208000003445 Mouth Neoplasms Diseases 0.000 claims 2
- 208000034578 Multiple myelomas Diseases 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 206010038389 Renal cancer Diseases 0.000 claims 2
- 206010041067 Small cell lung cancer Diseases 0.000 claims 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 2
- 208000024313 Testicular Neoplasms Diseases 0.000 claims 2
- 206010057644 Testis cancer Diseases 0.000 claims 2
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 2
- 206010046431 Urethral cancer Diseases 0.000 claims 2
- 206010046458 Urethral neoplasms Diseases 0.000 claims 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 2
- 201000010881 cervical cancer Diseases 0.000 claims 2
- 208000030381 cutaneous melanoma Diseases 0.000 claims 2
- 206010017758 gastric cancer Diseases 0.000 claims 2
- 208000005017 glioblastoma Diseases 0.000 claims 2
- 201000010536 head and neck cancer Diseases 0.000 claims 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims 2
- 208000016356 hereditary diffuse gastric adenocarcinoma Diseases 0.000 claims 2
- 206010073095 invasive ductal breast carcinoma Diseases 0.000 claims 2
- 201000010985 invasive ductal carcinoma Diseases 0.000 claims 2
- 201000010982 kidney cancer Diseases 0.000 claims 2
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 claims 2
- 201000007270 liver cancer Diseases 0.000 claims 2
- 208000014018 liver neoplasm Diseases 0.000 claims 2
- 201000005249 lung adenocarcinoma Diseases 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 208000020816 lung neoplasm Diseases 0.000 claims 2
- 201000005243 lung squamous cell carcinoma Diseases 0.000 claims 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 2
- 208000020984 malignant renal pelvis neoplasm Diseases 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- SKTCDJAMAYNROS-UHFFFAOYSA-N methoxycyclopentane Chemical compound COC1CCCC1 SKTCDJAMAYNROS-UHFFFAOYSA-N 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 2
- 201000002528 pancreatic cancer Diseases 0.000 claims 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 2
- 239000002244 precipitate Substances 0.000 claims 2
- 230000000306 recurrent effect Effects 0.000 claims 2
- 201000007444 renal pelvis carcinoma Diseases 0.000 claims 2
- 229920006395 saturated elastomer Polymers 0.000 claims 2
- 201000003708 skin melanoma Diseases 0.000 claims 2
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 2
- 201000011549 stomach cancer Diseases 0.000 claims 2
- 201000003120 testicular cancer Diseases 0.000 claims 2
- 201000002510 thyroid cancer Diseases 0.000 claims 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 2
- 238000004922 13C solid-state nuclear magnetic resonance spectroscopy Methods 0.000 claims 1
- 239000004471 Glycine Substances 0.000 claims 1
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 claims 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 1
- 239000012159 carrier gas Substances 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000007789 gas Substances 0.000 claims 1
- 238000010438 heat treatment Methods 0.000 claims 1
- -1 isomer 2 Chemical compound 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 238000010926 purge Methods 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 238000001228 spectrum Methods 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024136962A JP2024153948A (ja) | 2022-09-07 | 2024-08-16 | Ｆｇｆｒ３阻害剤の共結晶形態 |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263404232P | 2022-09-07 | 2022-09-07 | |
| US63/404,232 | 2022-09-07 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024136962A Division JP2024153948A (ja) | 2022-09-07 | 2024-08-16 | Ｆｇｆｒ３阻害剤の共結晶形態 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024037713A JP2024037713A (ja) | 2024-03-19 |
| JP2024037713A5 true JP2024037713A5 (enExample) | 2024-05-02 |
| JP7541606B2 JP7541606B2 (ja) | 2024-08-28 |
Family
ID=88204177
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023145013A Active JP7541606B2 (ja) | 2022-09-07 | 2023-09-07 | Ｆｇｆｒ３阻害剤の共結晶形態 |
| JP2024136962A Pending JP2024153948A (ja) | 2022-09-07 | 2024-08-16 | Ｆｇｆｒ３阻害剤の共結晶形態 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024136962A Pending JP2024153948A (ja) | 2022-09-07 | 2024-08-16 | Ｆｇｆｒ３阻害剤の共結晶形態 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20240116932A1 (enExample) |
| EP (1) | EP4584270A1 (enExample) |
| JP (2) | JP7541606B2 (enExample) |
| KR (1) | KR20250057022A (enExample) |
| CN (1) | CN120187720A (enExample) |
| AR (1) | AR130417A1 (enExample) |
| AU (1) | AU2023338199A1 (enExample) |
| CA (1) | CA3266872A1 (enExample) |
| CL (1) | CL2025000596A1 (enExample) |
| CO (1) | CO2025002467A2 (enExample) |
| CR (1) | CR20250077A (enExample) |
| DO (1) | DOP2025000054A (enExample) |
| IL (1) | IL319342A (enExample) |
| PE (1) | PE20251400A1 (enExample) |
| TW (1) | TWI862146B (enExample) |
| WO (1) | WO2024054814A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025259519A1 (en) | 2024-06-13 | 2025-12-18 | Eli Lilly And Company | Activation of egfr/her2/3 in cancer after treatment with an inhibitor of fibroblast growth factor receptor 3 (fgfr3) |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007067727A2 (en) | 2005-12-08 | 2007-06-14 | Ssci, Inc. | Metronidazole cocrystals and imipramine cocrystals |
| PH12012000132A1 (en) | 2011-06-09 | 2014-10-20 | Servier Lab | New co-crystals of agomelatine, a process for their preparation and pharmaceutical compositions containing them |
| CN102964384B (zh) | 2012-11-09 | 2015-06-24 | 中山大学 | 阿德福韦酯没食子酸共晶及其制备方法和组合物 |
| JP2021523876A (ja) | 2018-02-13 | 2021-09-09 | トランスジェネックス ナノバイオテック、インコーポレイテッド | 癌治療のためのタミバロテンの新規の結晶形態 |
| US12180207B2 (en) * | 2018-12-19 | 2024-12-31 | Array Biopharma Inc. | Substituted pyrazolo[1,5-a]pyridine compounds as inhibitors of FGFR tyrosine kinases |
| CN111574359A (zh) | 2019-02-19 | 2020-08-25 | 愈磐生物科技（苏州）有限公司 | 乐伐替尼-没食子酸共晶晶型及其应用 |
| CN113943284B (zh) | 2020-07-15 | 2023-12-19 | 中国医学科学院药物研究所 | 盐酸吡格列酮没食子酸共晶及制备方法和其组合物与用途 |
| TW202402754A (zh) | 2021-03-04 | 2024-01-16 | 美商美國禮來大藥廠 | Fgfr3抑制劑化合物 |
-
2023
- 2023-09-06 CN CN202380077374.0A patent/CN120187720A/zh active Pending
- 2023-09-06 CR CR20250077A patent/CR20250077A/es unknown
- 2023-09-06 KR KR1020257010708A patent/KR20250057022A/ko not_active Ceased
- 2023-09-06 PE PE2025000482A patent/PE20251400A1/es unknown
- 2023-09-06 US US18/462,286 patent/US20240116932A1/en active Pending
- 2023-09-06 IL IL319342A patent/IL319342A/en unknown
- 2023-09-06 CA CA3266872A patent/CA3266872A1/en active Pending
- 2023-09-06 AU AU2023338199A patent/AU2023338199A1/en active Pending
- 2023-09-06 EP EP23777475.7A patent/EP4584270A1/en active Pending
- 2023-09-06 WO PCT/US2023/073508 patent/WO2024054814A1/en not_active Ceased
- 2023-09-07 JP JP2023145013A patent/JP7541606B2/ja active Active
- 2023-09-07 TW TW112133993A patent/TWI862146B/zh active
- 2023-09-07 AR ARP230102376A patent/AR130417A1/es unknown
-
2024
- 2024-08-16 JP JP2024136962A patent/JP2024153948A/ja active Pending
-
2025
- 2025-02-28 CO CONC2025/0002467A patent/CO2025002467A2/es unknown
- 2025-03-04 CL CL2025000596A patent/CL2025000596A1/es unknown
- 2025-03-06 DO DO2025000054A patent/DOP2025000054A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6804647B2 (ja) | ピリミド［５，４−ｂ］インドリジン又はピリミド［５，４−ｂ］ピロリジン化合物、その製造方法及び用途 | |
| CN105452250B (zh) | 5,10‑亚甲基‑(6r)‑四氢叶酸的半硫酸盐 | |
| CN106749261A (zh) | 一类取代三唑并哌嗪类parp抑制剂及其制备方法和用途 | |
| KR102421137B1 (ko) | 아미노치환 질소함유 축합고리 화합물 및 그의 제조방법과 용도 | |
| US20230250074A1 (en) | Process for synthesis of quinazoline compounds | |
| JP2024037713A5 (enExample) | ||
| CN114364685A (zh) | 含氮杂环类化合物，及其制备方法、药物组合物和应用 | |
| JP2011515421A5 (enExample) | ||
| CN104926792B (zh) | 甲硝唑衍生物及其制备方法和用途 | |
| CN112334458A (zh) | 3-吲唑啉酮类化合物、其制备方法及其在医药学上的应用 | |
| CN103012248A (zh) | 氨基康普立停衍生物的合成及其作为口服抗肿瘤药物的应用 | |
| IL319342A (en) | Co-crystals of 4-[4-[3-chloro-4-[1-(2-pyridyl)-2-hydroxyethoxy]pyrazolo[1,5-A]pyridin-6-yl]-5-methyl-triazol-1-yl]piperidine-1-caridine-1-caridine and nicotinamide | |
| DK2020410T3 (en) | Pyrido [2,3-d] pyrimidine derivatives, the preparation thereof and therapeutic use | |
| ES2947326T3 (es) | Procedimiento de producción de un derivado de imidazo[1,2-b]piridazina 3,6-disubstituido | |
| ES2956847T3 (es) | Método mejorado para la fabricación de 3-[(1s)-1-imidazo[1,2-a]piridin-6-iletil]-5-(1-metilpirazol-4-il)triazolo[4,5-b]pirazina y formas polimórficas de la misma | |
| CN110105356A (zh) | 一种氮杂吲哚类化合物及其制备方法和用途 | |
| CN109384784B (zh) | 磺酰胺类衍生物、其制备方法及其在医药上的用途 | |
| CN110467601A (zh) | 一种吡唑联吡啶酮类化合物、中间体及其制备方法及应用 | |
| CN120058674A (zh) | 4（1h-吡唑-3-基）哌啶基衍生物及其制备方法与在制备mnk抑制剂中的应用 | |
| CN111233762B (zh) | 一种乐伐替尼与对羟基苯甲酸共晶及其制备方法 | |
| CN118525012A (zh) | 奥希替尼共晶及制备方法以及作为药物或在药物制剂中的应用 | |
| CN108383849B (zh) | 咪唑并喹唑啉衍生物及其在抗肿瘤抗炎中的应用 | |
| CN106146525A (zh) | 三并环类间变性淋巴瘤激酶抑制剂 | |
| CN111039940B (zh) | 一种Aurora A激酶抑制剂、制备方法、药物组合物及其用途 | |
| CN114426541B (zh) | 氮杂芳基化合物及其用途 |